Potential opportunities for (a) lives saved and (b) non-fatal events prevented and components of these benefits (with sensitivity analysis) through better application of treatments and possible innovations
| Deaths per 10 000 | Range in sensitivity analysis | Recurrent MI or stroke per 10 000 | Range in sensitivity analysis | |
| Total events: STEMI | 23 | 2 to 60 | 213 | 24 to 527 |
| Delayed presentation | 6 | 1 to 13 | 60 | 14 to 127 |
| Fibrinolysis rather than PPCI | 1 | 0 to 5 | 12 | 0 to 45 |
| Delayed PPCI | 3 | 0 to 10 | 38 | 0 to 92 |
| Delayed fibrinolysis | 1 | 0 to 3 | 11 | 1 to 26 |
| No reperfusion | 7 | 3 to 17 | 83 | 25 to 161 |
| Delayed invasive management | 0 | 0 to 1 | 2 | 0 to 4 |
| No invasive management | 1 | 0 to 7 | 5 | 0 to 27 |
| Total Events: NSTEMI | 43 | 0 to 177 | 55 | 0 to183 |
| Delay invasive management | 4 | 0 to 10 | 3 | 0 to 8 |
| No invasive management | 16 | 0 to 87 | 11 | 0 to 67 |
| No GP | 21 | 0 to 59 | 40 | 0 to 96 |
| Total events: secondary prevention treatments | 104 | 27 to 266 | 191 | 61 to 605 |
| Lack of prescription | 46 | 16 to 101 | 121 | 36 to 229 |
| Non-adherence | 58 | 11 to 165 | 69 | 24 to 376 |
| Putative novel therapy | Optimal* | All† | Optimal | All |
| 10% Reduction | 1 | 34 | 4 | 96 |
| 20% Reduction | 3 | 67 | 9 | 192 |
| 30% Reduction | 4 | 101 | 13 | 288 |
-
*Optimal—for patients with STEMI: reperfusion, early invasive management and GP IIb/IIIa inhibition; for patients with NSTEMI: early invasive management and GP IIb/IIIa inhibition; for secondary prevention: four or five guideline recommended treatments at discharge and adherent at 6 months; †All–a benefit that applies to the entire population.
-
GP, glycoprotein; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
